GSK1059615 is a PI3K and mTOR dual inhibitor [1
]. Some data on this compound is nested in a paper characterising GSK2126458 that we have as Omipalisib
. GSK1059615 was later reported to inhibited survival and proliferation of established (SCC-9, SQ20B and A253 lines) and primary human HNSCC cells, possibly the latter via programmed necrosis pathway [2
] . However,a Phase 1 dose-escalation study against solid tumors or lymphoma was terminated prematurely (July 2017) due to lack of sufficient exposure.